Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients

被引:93
|
作者
de Glas, Nienke A. [1 ,2 ]
Kiderlen, Mandy [1 ,2 ]
Vandenbroucke, Jan P. [3 ]
de Craen, Anton J. M. [2 ]
Portielje, Johanneke E. A. [5 ]
de Velde, Cornelis J. H. van [1 ]
Liefers, Gerrit-Jan [1 ]
Bastiaannet, Esther [1 ,2 ]
Le Cessie, Saskia [3 ,4 ]
机构
[1] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Postzone K6-R,POB 9600, NL-2300 RC Leiden, Netherlands
[5] Haga Hosp, Dept Med Oncol, The Hague, Netherlands
来源
关键词
KAPLAN-MEIER METHOD; SUBDISTRIBUTION; MODELS; IMPACT; DEATH; WOMEN;
D O I
10.1093/jnci/djv366
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An important consideration in studies that use cause-specific endpoints such as cancer-specific survival or disease recurrence is that risk of dying from another cause before experiencing the event of interest is generally much higher in older patients. Such competing events are of major importance in the design and analysis of studies with older patients, as a patient who dies from another cause before the event of interest cannot reach the endpoint. In this Commentary, we present several clinical examples of research questions in a population-based cohort of older breast cancer patients with a high frequency of competing events and discuss implications of choosing models that deal with competing risks in different ways. We show that in populations with high frequency of competing events, it is important to consider which method is most appropriate to estimate cause-specific endpoints. We demonstrate that when calculating absolute cause-specific risks the Kaplan-Meier method overestimates risk of the event of interest and that the cumulative incidence competing risks (CICR) method, which takes competing risks into account, should be used instead. Two approaches are commonly used to model the association between prognostic factors and cause-specific survival: the Cox proportional hazards model and the Fine and Gray model. We discuss both models and show that in etiologic research the Cox Proportional Hazards model is recommended, while in predictive research the Fine and Gray model is often more appropriate. In conclusion, in studies with cause-specific endpoints in populations with a high frequency of competing events, researchers should carefully choose the most appropriate statistical method to prevent incorrect interpretation of results.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] COMPETING RISKS DETERMINING EVENT-FREE SURVIVAL IN EARLY BREAST-CANCER
    ARRIAGADA, R
    RUTQVIST, LE
    KRAMAR, A
    JOHANSSON, H
    BRITISH JOURNAL OF CANCER, 1992, 66 (05) : 951 - 957
  • [22] Competing Risks for a Diagnosis of Invasive Breast Cancer
    Syn, Nicholas L.
    JAMA ONCOLOGY, 2019, 5 (01) : 110 - 111
  • [23] Competing risks to breast cancer mortality in Catalonia
    Ester Vilaprinyo
    Rosa Gispert
    Montserrat Martínez-Alonso
    Misericòrdia Carles
    Roger Pla
    Josep-Alfons Espinàs
    Montserrat Rué
    BMC Cancer, 8
  • [24] Competing risks to breast cancer mortality in Catalonia
    Vilaprinyo, Ester
    Gispert, Rosa
    Martinez-Alonso, Montserrat
    Carles, Misericordia
    Pla, Roger
    Espinas, Josep-Alfons
    Rue, Montserrat
    BMC CANCER, 2008, 8 (1) : 331
  • [25] Competing Risks in Older Patients With Cancer: A Systematic Review of Geriatric Oncology Trials
    Burdett, Nikki
    Vincent, Andrew D.
    O'Callaghan, Michael
    Kichenadasse, Ganessan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (08): : 825 - 830
  • [26] Joint modelling of longitudinal and survival data in the presence of competing risks with applications to prostate cancer data
    Sheikh, Md Tuhin
    Ibrahim, Joseph G.
    Gelfond, Jonathan A.
    Sun, Wei
    Chen, Ming-Hui
    STATISTICAL MODELLING, 2021, 21 (1-2) : 72 - 94
  • [27] Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis
    Zhou, Ping
    Zhang, Wen-Wen
    Bao, Yong
    Wang, Jun
    Lian, Chen-Lu
    He, Zhen-Yu
    Wu, San-Gang
    BREAST, 2020, 54 : 319 - 327
  • [28] Postoperative cure in Iranian patients with gastric cancer: estimating the crude conditional probability in a relative survival setting in the presence of competing risks
    Paknazar, Fatemeh
    Mahmoudi, Mahmood
    Mohammad, Kazem
    Zeraati, Hojjat
    Mansournia, Mohammad Ali
    Yaseri, Mehdi
    ASIAN BIOMEDICINE, 2017, 11 (06) : 461 - 467
  • [29] Competing risks analysis in cancer clinical trials
    Tai, BC
    Machin, D
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 35 - 35
  • [30] A competing risks analysis of the association between prediagnostic serum glucose and lipids and breast cancer survival
    Wulaningsih, W.
    Vandaninia, M.
    Rowley, M.
    Holmberg, L.
    Garmo, H.
    Malmstrom, H.
    Lambe, M.
    Hammar, N.
    Walldius, G.
    Jungner, I.
    Coolen, A.
    Van Hemelrijck, M.
    CANCER RESEARCH, 2016, 76